Self-Assembling Anti-Cancer Molecules Created in Minutes: like 'LEGO Death Star'?
Researchers have developed a simple and versatile method for making artificial anti-cancer molecules that mimic the properties of one of the body’s natural defence systems.
The chemists, led by Professor Peter Scott at the University of Warwick, UK, have been able to produce molecules that have a similar structure to peptides which are naturally produced in the body to fight cancer and infection.
Published in Nature Chemistry, the molecules produced in the research have proved effective against colon cancer cells in laboratory tests, in collaboration with Roger Phillips at the Institute for Cancer Therapeutics, Bradford, UK.
Artificial peptides had previously been difficult and prohibitively expensive to manufacture in large quantities, but the new process takes only minutes and does not require costly equipment. Also, traditional peptides that are administered as drugs are quickly neutralised by the body’s biochemical defences before they can do their job.
A form of complex chemical self-assembly, the new method developed at Warwick addresses these problems by being both practical and producing very stable molecules. The new peptide mimics, called triplexes, have a similar 3D helix form to natural peptides.
“The chemistry involved is like throwing Lego blocks into a bag, giving them a shake, and finding that you made a model of the Death Star” says Professor Scott. “The design to achieve that takes some thought and computing power, but once you’ve worked it out the method can be used to make a lot of complicated molecular objects.”
Describing the self-assembly process behind the artificial peptides Professor Scott says: “When the organic chemicals involved, an amino alcohol derivative and a picoline, are mixed with iron chloride in a solvent, such as water or methanol, they form strong bonds and are designed to naturally fold together in minutes to form a helix. It’s all thermodynamically downhill. The assembly instructions are encoded in the chemicals themselves.”
“Once the solvent has been removed we are left with the peptide mimics in the form of crystals”, says Professor Scott. “There are no complicated separations to do, and unlike a Lego model kit there are no mysterious bits left over. In practical terms, the chemistry is pretty conventional. The beauty is that these big molecules assemble themselves. Nature uses this kind of self-assembly to make complex asymmetric molecules like proteins all the time, but doing it artificially is a major challenge.”
Whilst the peptide mimics created by the process have been successful in laboratory tests on colon cancer cells they will require further research before they can be used in clinical trials on patients. Nevertheless they are made of simple building blocks and in early tests the team have shown that they have very low toxicity to bacteria. “This is very unusual and promising selectivity,” says Professor Scott.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance